Chavez-MacGregor et al. showed that time to chemotherapy >60 days influenced survival outcomes, particularly for patients with Stage III, triple-negative breast cancer, and HER2-positive tumors [19]. Here, ERBB2 is linked to triple-negative breast carcinoma.